Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$68.12 USD

68.12
5,481,354

+1.62 (2.44%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $68.12 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Edwards Lifesciences (EW) Up 2% Since Last Earnings Report: Can It Continue?

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth

With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.

HOLX or EW: Which Is the Better Value Stock Right Now?

HOLX vs. EW: Which Stock Is the Better Value Option?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

If You Invested $1000 in Edwards Lifesciences a Decade Ago, This is How Much It'd Be Worth Now

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Fresenius Medical (FMS) Q4 Earnings Beat, Operating Margin Up

Fresenius Medical's (FMS) fourth-quarter revenues suffer due to unfavorable currency movement. However, the company???s transformational plans continue to benefit its operating income.

Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

Here's Why You Should Add Masimo (MASI) to Your Portfolio Now

Masimo's (MASI) R&D activities raise optimism about the stock.

Edwards (EW) Gains From Balanced Core Growth and New Launches

Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.

Mark Vickery headshot

Top Research Reports for Alibaba, General Electric & Honeywell

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), General Electric Company (GE) and Honeywell International Inc. (HON).

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics

Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.

Urmimala Biswas headshot

3 Medtech Stocks Likely to Top Estimates This Earnings Season

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip

Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.

Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Edwards Lifesciences (EW) Q4 Earnings Match Estimates

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 2.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

ITGR or EW: Which Is the Better Value Stock Right Now?

ITGR vs. EW: Which Stock Is the Better Value Option?

Stay Ahead of the Game With Edwards Lifesciences (EW) Q4 Earnings: Wall Street's Insights on Key Metrics

Beyond analysts' top -and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Strength Seen in Edwards Lifesciences (EW): Can Its 6.2% Jump Turn into More Strength?

Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

ITGR vs. EW: Which Stock Is the Better Value Option?

ITGR vs. EW: Which Stock Is the Better Value Option?

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

ITGR vs. EW: Which Stock Should Value Investors Buy Now?

ITGR vs. EW: Which Stock Is the Better Value Option?

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.